Sildenafil citrate salt

SKU: S0078

Category: API's & Intermediates

Synonyms: 5-[2-Ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-4H-pyrazolo[5,4-e]pyrimidin-7-one citrate salt , Actra-Rx , Edegra , Viagra , Tonafil , Apodefil , UK 92480; 171599-83-0
CAS-Number: C₂₂H₃₀N₆O₄S . C₆H₈O₇
Molecular Formula: 474.6 . 192.1
Molecular Weight

Product Data
Handling
Safety Information
Details

Specifications

Purity: ≥98% (HPLC)
Identity: 1H-NMR
Appearance: White to off-white powder

Properties

Solvents: DMSO (20 mg/ml)

Handling Advice: Protect from light and moisture.
Use / Stability: Stable for at least 2 years after receipt when stored at +4°C.
Long Term Storage: +4°C
Short Term Storage: RT
Shipping: AMBIENT

Transportation: Not dangerous goods
Signal word: Warning
GHS Symbol: GHS07
Precautionary statements: P261-P305 + P351 + P338
Hazard statements: H315-H319-H335

Description: Potent cGMP-specific phosphodiesterase inhibitor that is highly selective for PDE5. It inhibits PDE5 activity in isolated rabbit platelets with an IC50 value of 3.6nM (3nM in human corpus cavernosum) compared to inhibition of PDE1 and PDE3 activities (IC50s = 0.26 and 65?M, respectively). Inhibition of PDE5 enhances the relaxation of smooth muscle in a range of vascular tissues by prolonging the nitric oxide/cGMP-mediated activation of cGMP-dependent protein kinase. While most notable for its use in the treatment of erectile dysfunction, sildenafil’s vasorelaxant properties have also been used to control vascular tone in pulmonary arterial hypertension and high-altitude pulmonary edema associated with altitude sickness. The citrate salt has superior water solubility and pharmacokinetics compared to the base salt of sildenafil.
InChi: InChI=1S/C22H30N6O4S.C6H8O7/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28,7-3(8)1-6(13,5(11)12)2-4(9)10/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29),13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
References: (1) N.K. Terrett, et al., Bioorg. Med. Chem. Lett. 6, 1819 (1996) , (2) J. Richalet, et al., Am. J. Respir. Crit. Care Med. 171, 275 (2005) , (3) C.E. Teixeira, et al., J. Pharmacol. Exp. Ther. 316, 654 (2006) , (4) S. Jung, et al., Arch. Pharm. Res. 34, 451 (2011)
InChi Key: DEIYFTQMQPDXOT-UHFFFAOYSA-N
Smiles: O=C1NC(C2=CC(S(=O)(N3CCN(C)CC3)=O)=CC=C2OCC)=NC4=C1N(C)N=C4CCC.OC(CC(O)=O)(CC(O)=O)C(O)=O

Potent cGMP-specific phosphodiesterase inhibitor that is highly selective for PDE5. It inhibits PDE5 activity in isolated rabbit platelets with an IC50 value of 3.6nM (3nM in human corpus cavernosum) compared to inhibition of PDE1 and PDE3 activities (IC50s = 0.26 and 65?M, respectively). Inhibition of PDE5 enhances the relaxation of smooth muscle in a range of vascular tissues by prolonging the nitric oxide/cGMP-mediated activation of cGMP-dependent protein kinase. While most notable for its use in the treatment of erectile dysfunction, sildenafil’s vasorelaxant properties have also been used to control vascular tone in pulmonary arterial hypertension and high-altitude pulmonary edema associated with altitude sickness. The citrate salt has superior water solubility and pharmacokinetics compared to the base salt of sildenafil.

SKU: S0078 Category: API's & Intermediates

Additional information

Additional information

Synonyms	5-[2-Ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-4H-pyrazolo[5,4-e]pyrimidin-7-one citrate salt, Actra-Rx, Edegra, Viagra, Tonafil, Apodefil, UK 92480
Purity	≥98% (HPLC)
Appearance	White to off-white powder
CAS-Number	171599-83-0
Molecular Formula	C22H30N6O4S . C6H8O7
Molecular Weight	474.6 . 192.1
Identity	1H-NMR
Solvents	DMSO (20 mg/ml)
Smiles	O=C1NC(C2=CC(S(=O)(N3CCN(C)CC3)=O)=CC=C2OCC)=NC4=C1N(C)N=C4CCC.OC(CC(O)=O)(CC(O)=O)C(O)=O
InChi Key	DEIYFTQMQPDXOT-UHFFFAOYSA-N
Shipping	AMBIENT
Short Term Storage	RT
Long Term Storage	+4°C
Handling Advice	Protect from light and moisture.
Use / Stability	Stable for at least 2 years after receipt when stored at +4°C.
Hazard statements	H315-H319-H335
Precautionary statements	P261-P305 + P351 + P338
GHS Symbol	GHS07
Signal word	Warning
Transportation	Not dangerous goods
References	(1) N.K. Terrett, et al., Bioorg. Med. Chem. Lett. 6, 1819 (1996), (2) J. Richalet, et al., Am. J. Respir. Crit. Care Med. 171, 275 (2005), (3) C.E. Teixeira, et al., J. Pharmacol. Exp. Ther. 316, 654 (2006), (4) S. Jung, et al., Arch. Pharm. Res. 34, 451 (2011)
InChi	InChI=1S/C22H30N6O4S.C6H8O7/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28,7-3(8)1-6(13,5(11)12)2-4(9)10/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29),13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
Quantity	50 mg, 250 mg, Bulk